CytoMed Therapeutics
GDTC
1 hedge funds and large institutions have $165 invested in CytoMed Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$168 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $165 | +$168 | +54 | New |
|
GDTC Hedge Fund Activity: Q2 2023 in Review
1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q2 2023, worth a combined $165.
Buyers outnumbered sellers: 1 fund opened new GDTC positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $168.
- 1 institutional investor held CytoMed Therapeutics (GDTC) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $165 of CytoMed Therapeutics stock for Q2 2023.
- 1 fund opened new CytoMed Therapeutics positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest CytoMed Therapeutics buyer in Q2 2023 was UBS Group, an estimated $168 added.
Based on aggregated 13F filings for Q2 2023.